Atomwise and Charles River Laboratories Form a Strategic Alliance to Provide Premier Artificial Intelligence-Powered Drug Discovery Capabilities

Charles River’s clients gain access to Atomwise’s Artificial
Intelligence (AI) technology to improve novelty, quality and efficiency
of preclinical drug discovery.

SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, Inc. today announced a strategic alliance with Charles River
Laboratories International, Inc., which will offer biotech and
pharmaceutical companies an end-to-end drug discovery solution that
unites AI technology with premium research services. Under the
agreement, Atomwise will support hit discovery, hit-to-lead, and lead
optimization efforts; while receiving technology access fees,
milestone-based payments and royalties from clients.

“We’re pleased to partner with Charles River, the leading global
discovery and safety CRO,” said Atomwise CEO Dr. Abraham Heifets. He
added, “Biopharmaceutical companies around the world trust Charles River
with moving their discoveries from an idea into the clinic, and Charles
River trusts us to enhance that process with our innovative AI
technology. Through this collaboration, we will bring our technology and
experience in drug discovery to more biotech and pharma partners,
furthering our mission to discover and develop new medicines for
patients.”

Biotech and pharmaceutical companies will now have the ability to better
identify chemically diverse hit compounds. Historically, the challenge
has been finding the right drug among the trillions of possibilities
that meets their needs for potency, selectivity, toxicity, efficacy,
safety, and patentability. Brute force physical screening is no longer a
solution, with billions of commercially available compounds and billions
more that are synthesizable. Additionally, the most valuable target
classes are among the least studied and require exploration beyond the
reach of common libraries and assays. Atomwise can screen billions of
compounds and has demonstrated success using homology-modeled proteins.
With Atomwise, historically intractable targets become new therapeutic
opportunities.

Under the agreement, Atomwise will make its technology available for
multiple projects. The commercial terms of the agreement include a
technology access fee for each project and payments for successes in hit
discovery, hit-to-lead, and lead optimization. Atomwise will also
receive royalties from clients on the sales of any compounds
commercialized. Based on calculations using historical industry average
lifetime revenues for small molecule drugs, Atomwise projects that the
total potential value of the royalties to Atomwise with success in all
projects could exceed US$2.4 billion.

About Atomwise
Atomwise, Inc. invented the first deep
learning AI technology for structure-based small molecule drug
discovery. Created in 2012, today Atomwise performs hundreds of projects
per year in partnership with some of the world’s largest pharmaceutical
and agrochemical companies, as well as more than one hundred
universities and hospitals in 19 countries. Atomwise has raised over $50
million from leading venture capital firms to support the development
and application of its AI technology.

Contacts

Sara Dunn
sdunn@jpa.com
202-591-4045